Next 10 |
A recently published review has determined that using psilocybin to manage mental-health conditions doesn’t heighten the risk of paranoia. This discovery comes at a time when public interest in the therapeutic potential of psychedelics is increasing. The review was carried out by resea...
Recent research assessed how patient expectations influenced the outcomes of psychedelic treatments in comparison to conventional treatments. This comes as the global impact of depression is being felt in different parts of the world and the need for alternative treatments increases. For a lo...
2024-03-22 13:53:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seelos Therapeutics (NASDAQ: SEEL ) just reported results for the fourth quarter of 2023. Seelos Therapeutics reported earnings per share of -79 cents. This was above the ...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 9.8% to $0.133 on volume of 209,262,975 shares Ontrak Inc. (OTRK) rose 131.6% to $0.44 on volume of 206,699,914 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.7% to $3.65 on volume of 1...
New research has discovered that psilocybin decreases the amygdala region’s response to seeing images of angry faces. The amygdala is responsible for processing emotions, particularly those linked to anxiety and fear. This region in the brain also links emotions to other things such as ...
A look at the top 10 most actives in the United States Ontrak Inc. (OTRK) rose 214.5% to $0.5975 on volume of 79,666,583 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $3.7703 on volume of 36,416,698 shares Enveric Biosciences Inc. (ENVB) rose 35.5% to $1.49 on vol...
2024-03-19 09:09:46 ET More on Seelos Therapeutics Seelos Therapeutics files for 3.4M shares secondary offering Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Seeking Alpha’s Quant Rating on Seelos Therapeutics Histo...
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) PR Newswire NEW YORK , March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceu...
2024-03-18 03:35:04 ET More on Seelos Therapeutics Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Seelos Therapeutics announces equity and warrants offering for gross proceeds of $4M Seeking Alpha’s Quant Rating on Seelos Th...
2024-03-07 11:29:12 ET More on Clearmind Medicine, Bright Minds, etc. Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
News, Short Squeeze, Breakout and More Instantly...
Seelos Therapeutics Inc. Company Name:
SEEL Stock Symbol:
NYSE Market:
Seelos Therapeutics Inc. Website:
A recently published review has determined that using psilocybin to manage mental-health conditions doesn’t heighten the risk of paranoia. This discovery comes at a time when public interest in the therapeutic potential of psychedelics is increasing. The review was carried out by resea...
Recent research assessed how patient expectations influenced the outcomes of psychedelic treatments in comparison to conventional treatments. This comes as the global impact of depression is being felt in different parts of the world and the need for alternative treatments increases. For a lo...